Immunization News and Research

RSS

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

In a recently published article in the journal Cell Reports, scientists have demonstrated that individuals with or without a history of coronavirus disease 2019 (COVID-19) exhibit differential humoral and cellular immune responses 14 days after receiving mRNA-based COVID-19 vaccine developed by Pfizer/BioNTech. However, at a later time point, the responses become comparable between the two groups.

9 Jan 2022

Characteristics of initial hospitalization and readmissions among pediatric patients with COVID-19 in the US

Researchers from various institutions describe the characteristics, costs, and healthcare resource use associated with pediatric COVID-19 patients.

7 Jan 2022

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

Researchers examine the efficacy of mRNA COVID-19 vaccination in NSCLC patients.

6 Jan 2022

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

The purpose of this study was to determine the breadth of neutralizing activity generated by exposure to certain SARS-CoV-2 variants, vaccinations, or both.

6 Jan 2022

Study findings suggest spread of Omicron can be ascribed to immune evasiveness rather than an increase in transmissibility

Researchers investigate the household transmission of the Omicron VOC and increased immune evasiveness of both the Omicron and Delta variants

5 Jan 2022

Oral bacteria-based SARS-CoV-2 vaccine platform

In a new study, researchers engineered the bacterial strain, Salmonella, to express differently-sized antigens to serve as vaccine platforms.

5 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

In a new study, a team of researchers from multi-national institutions discovered that 70-80% of CD4 and CD8 T cell responses to spike were consistent across research groups. Moreover, although having far more mutations, the magnitude of Omicron cross-reactive T cells was comparable to that of the Beta and Delta variants.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

WHO lists the Comirnaty COVID-19 mRNA vaccine for emergency use

The World Health Organization today listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO since the outbreak began a year ago.

2 Jan 2022

COVID-19 vaccine appears safe in children aged 5–11 Years

A new report notes menial or nil severe adverse events from vaccination against COVID-19 in children and therefore recommends COVID-19 vaccination among children aged 5-11 years old.

31 Dec 2021

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

Researchers evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with inflammatory bowel disease.

30 Dec 2021

COVID mRNA vaccines show diminished neutralization responses against Omicron

Researchers report an overview of antibody neutralization by all currently approved vaccines against the SARS-CoV-2 Omicron, Beta, and Delta VOCs.

29 Dec 2021

Impact of an omicron outbreak at a private gathering in the Faroe Islands

New findings suggest that the Omicron variant has potent immune-escape capabilities, putting even newly boosted patients at risk of infection.

29 Dec 2021

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

A new study found that the presence of a subset of antibodies with broad neutralizing activities against all circulating variants of concern in the three-dose vaccines' memory B-derived antibody repertoire suggests that the Omicron/future variants infection may elicit selective and rapid recall of humoral responses, conferring secondary protection directed by memory etched in the immune system.

29 Dec 2021

Immunization News and Research

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

Characteristics of initial hospitalization and readmissions among pediatric patients with COVID-19 in the US

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

Study findings suggest spread of Omicron can be ascribed to immune evasiveness rather than an increase in transmissibility

Oral bacteria-based SARS-CoV-2 vaccine platform

Israeli study confirms drop in BNT162b2 efficacy after six months

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

WHO lists the Comirnaty COVID-19 mRNA vaccine for emergency use

COVID-19 vaccine appears safe in children aged 5–11 Years

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

COVID mRNA vaccines show diminished neutralization responses against Omicron

Impact of an omicron outbreak at a private gathering in the Faroe Islands

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Importance of booster vaccine doses for maintaining protection against the SARS-CoV-2 Omicron variant

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News